子宫癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

子宫癌治疗和诊断市场按癌症类型(子宫内膜腺癌、腺鳞癌、乳头状浆液性癌、子宫肉瘤)、产品和地理细分

市场快照

Uterine Cancer Therapeutics & Diagnostics Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6 %
Uterine Cancer Therapeutics & Diagnostics Market Major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于对子宫癌的认识不断提高和医疗保健支出增加,预计子宫癌治疗和诊断市场的复合年增长率将达到 6%。在美国,九月是妇科癌症宣传月。美国癌症研究协会在其文章中指出,子宫内膜癌在全球很常见,而子宫肉瘤被认为是一种罕见的癌症。疾病预防控制中心表示,大约 68% 的子宫癌是子宫内膜癌。

此外,像印度这样的发展中国家有一个国家癌症控制计划,该计划于 1975-76 年建立。这有助于发展区域癌症中心 (RCC)、医学院的肿瘤学部门以及支持购买远程治疗机器。在这个国家,正在开展有关癌症的宣传计划,使妇女意识到这种疾病的严重性。

鉴于疾病的严重程度和女性健康的重要性,医疗保健提供者和政府正在北美、欧洲和亚太地区等某些地区开展宣传计划。随着政府和医疗保健提供者的日益关注,表明市场将在预测期内迅速增长。

报告范围

根据报告的范围,子宫癌是一种常见的女性生殖系统癌症,起源于子宫内膜。市场按癌症类型、治疗学、诊断学和地理划分。

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Therapeutics
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Others
Diagnostics
Biopsy
Pelvic Ultrasound
Hysteroscopy
Dilation and Curettage
CT Scan
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

子宫内膜腺癌见证了预测期内的最高增长

预计子宫内膜腺癌日益增加的负担将推动该领域的子宫癌治疗和诊断市场。根据 Cancer.gov 的数据,子宫内膜腺肉瘤是女性中最常见的癌症类型,大约 80% 的子宫癌是腺癌,其严重程度各不相同。

女性肥胖的增加被认为是导致子宫内膜癌发病率增加的主要因素,因为大约 90% 的子宫癌会影响子宫内膜。随着该病发病率的增加和对该病认识的提高,相信该细分市场将在未来出现快速增长。

Uterine Cancer Therapeutics & Diagnostics Market  Trends

预计北美将在预测期内主导市场

北美地区被认为在不久的将来将主导全球子宫癌治疗和诊断市场。该地区市场增长的主要原因是该疾病发病率的上升和普通人群的意识增强。美国癌症协会估计,到 2020 年,美国约有 65,620 例子宫体癌新病例。此外,大约 10% 的子宫体癌是肉瘤。此外,诊断技术的快速进步和该国对新技术的更快采用正在推动所研究市场的整体增长。

Uterine Cancer Therapeutics & Diagnostics Market Share

竞争格局

所研究的市场具有中等竞争力,大多数与该市场打交道的公司都是全球参与者。然而,随着技术的不断进步,小公司也开始关注市场渗透,并努力抢占足够的市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. 5.2.1.1 Surgery

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Chemotherapy

        5. 5.2.1.5 Others

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Pelvic Ultrasound

        3. 5.2.2.3 Hysteroscopy

        4. 5.2.2.4 Dilation and Curettage

        5. 5.2.2.5 CT Scan

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Ariad Pharmaceuticals, Inc.

      2. 6.1.2 Abbott Laboratories

      3. 6.1.3 Becton, Dickinson & Co.

      4. 6.1.4 GlaxoSmithKline Plc

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Novartis AG

      7. 6.1.7 Sanofi

      8. 6.1.8 Siemens Healthcare Inc.

      9. 6.1.9 Roche Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Uterine Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Uterine Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, Becton Dickinson and Company, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc. are the major companies operating in Uterine Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!